MCID: RNL101
MIFTS: 61

Renal Cell Carcinoma, Papillary malady

Categories: Genetic diseases, Rare diseases, Nephrological diseases, Cancer diseases

Aliases & Classifications for Renal Cell Carcinoma, Papillary

About this section

Aliases & Descriptions for Renal Cell Carcinoma, Papillary:

Name: Renal Cell Carcinoma, Papillary 49 11
Papillary Renal Cell Carcinoma 32 10 45 12 51 65
Papillary Renal Cell Carcinoma, Sporadic 36 65
Renal Cell Carcinoma Xp11-Associated 67 24
Renal Cell Carcinoma, Papillary, 1 49 11
Renal Cell Carcinoma Papillary 1 67 24
Rccp 45 67
Renal Cell Carcinoma, Papillary, 1, Familial and Somatic 49
Papillary Renal Cell Carcinoma, Bilateral - 45
Papillary Renal Cell Carcinoma, Multiple - 45
Papillary Renal Cell Carcinoma, Familial - 45
Papillary Renal Cell Carcinoma, Sporadic - 45
Sporadic Papillary Renal Cell Carcinoma 10
 
Papillary Renal Carcinoma, Malignant - 45
Renal Cell Carcinoma, Xp11-Associated 65
Papillary Renal Cell Adenocarcinoma 51
Chromophilic Renal Cell Carcinoma 67
Renal Cell Carcinoma Papillary 67
Chromophil Carcinoma of Kidney 10
Papillary Kidney Carcinoma 10
Papillary Renal Carcinoma 22
Papillary Renal Cancer 22
Renal Cell Carcinoma 65
Renal Adenocarcinoma 45
Rccx1 67
Prcc 67

Characteristics:

HPO:

61
renal cell carcinoma, papillary:
Onset and clinical course: incomplete penetrance
Inheritance: autosomal dominant inheritance
renal cell carcinoma, papillary, 1:
Inheritance: somatic mutation


Classifications:



External Ids:

Disease Ontology10 DOID:4465
SNOMED-CT59 4797003
Orphanet51 319298
ICD10 via Orphanet28 C64
UMLS via Orphanet66 C1306837
UMLS65 C1306837, C1336078, C3275446

Summaries for Renal Cell Carcinoma, Papillary

About this section
OMIM:49 Xp11 translocation renal cell carcinomas (RCCX1) are a group of neoplasms distinguished by chromosomal translocations... (300854) more...

MalaCards based summary: Renal Cell Carcinoma, Papillary, also known as papillary renal cell carcinoma, is related to renal cell carcinoma and clear cell papillary renal cell carcinoma, and has symptoms including papillary renal cell carcinomaand renal cell carcinoma. An important gene associated with Renal Cell Carcinoma, Papillary is MET (MET Proto-Oncogene, Receptor Tyrosine Kinase), and among its related pathways are Transcriptional misregulation in cancer and Pathways in cancer. The drugs medroxyprogesterone and medroxyprogesterone acetate have been mentioned in the context of this disorder. Affiliated tissues include kidney, lung and bone, and related mouse phenotypes are craniofacial and renal/urinary system.

Disease Ontology:10 A renal cell carcinoma that is characterized by the development of multiple, bilateral papillary renal tumors.

NIH Rare Diseases:45 Papillary renal cell carcinoma (prcc) is a type of cancer that occurs in the kidneys. it accounts for about 10-15% of all renal cell carcinomas.renal cell carcinomas are a type of kidney cancer that develop in the lining of very small tubes (tubules) in the kidney.the term "papillary" describes the finger-like projections that can be found in most of the tumors. prcc can be divided into two types: type 1, which is more common and usually grows more slowly and type 2, which are usually more aggressive .though the exact cause of papillary renal cell carcinoma is unknown, smoking, obesity, and genetic predisposition conditions (such as hereditary leiomyomatosis and renal cell cancer) may contribute to the development of this type of cancer. treatment often begins with surgery to remove as much of the cancer as possible, and may be followed by radiation therapy, chemotherapy, biological therapy, or targeted therapy. last updated: 2/11/2016

UniProtKB/Swiss-Prot:67 Renal cell carcinoma papillary: A subtype of renal cell carcinoma tending to show a tubulo-papillary architecture formed by numerous, irregular, finger-like projections of connective tissue. Renal cell carcinoma is a heterogeneous group of sporadic or hereditary carcinoma derived from cells of the proximal renal tubular epithelium. Renal cell carcinoma Xp11-associated: Renal cell carcinoma is a heterogeneous group of sporadic or hereditary carcinoma derived from cells of the proximal renal tubular epithelium. It is subclassified into clear cell renal carcinoma (non- papillary carcinoma), papillary renal cell carcinoma, chromophobe renal cell carcinoma, collecting duct carcinoma with medullary carcinoma of the kidney, and unclassified renal cell carcinoma. RCCX1 histology shows both clear cells and papillary architecture, often with abundant psammoma bodies, although variable histologic features have been observed.

Description from OMIM:49 605074

Related Diseases for Renal Cell Carcinoma, Papillary

About this section

Diseases in the Renal Cell Carcinoma, Papillary family:

Hereditary Papillary Renal Cell Carcinoma

Diseases related to Renal Cell Carcinoma, Papillary via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 267)
idRelated DiseaseScoreTop Affiliating Genes
1renal cell carcinoma30.9AMACR, ASPSCR1, CA9, CDH16, FH, FLCN
2clear cell papillary renal cell carcinoma12.6
3hereditary papillary renal cell carcinoma12.5
4familial renal papillary carcinoma11.6
5chromophil renal cell carcinoma11.5
6kidney cancer11.3
7leiomyomatosis and renal cell cancer10.8
8hereditary persistence of fetal hemoglobin-beta-thalassemia syndrome10.6MET, PRCC
92p21 microdeletion syndrome10.6ASPSCR1, TFE3
10waardenburg syndrome, type 2a10.5MITF, TFE3
11metanephric adenoma10.5
12lymphangiosarcoma10.5FH, MITF
13sarcomatoid renal cell carcinoma10.5MME, PRCC
14gangliocytoma10.5KIT, MITF
15hypervitaminosis d10.5KIT, MITF
1646xy sex reversal 510.5ASPSCR1, MET, TFE3
17nephrogenic adenoma10.5KRT7, PAX8
18gastrointestinal system benign neoplasm10.4KRT7, PAX8
19rhinitis10.4KIT, PAX8
20breast papillomatosis10.4KIT, MME
21hepatic osteogenic sarcoma10.4KIT, MET
22cervical adenocarcinoma10.4KRT7, MME
23scrotal angioma10.4KRT7, MME
24acinar cell carcinoma10.4AMACR, KIT
25peptic ulcer perforation10.4MME, PAX8
26skin benign neoplasm10.4KIT, MITF
27hepatorenal syndrome10.4KRT7, MME
28female breast upper-inner quadrant cancer10.4KRT7, MME
29adult epithelioid sarcoma10.4KIT, KRT7
30breast ductal carcinoma10.4KRT7, MME
31liver rhabdomyosarcoma10.4ASPSCR1, KIT, TFE3
32renal tubular transport disease10.4AMACR, MET, PAX8
33mediastinum seminoma10.4FH, FLCN, MET
34hyperaldosteronism10.4FH, FLCN, MET
35malignant dermis tumor10.4FH, MITF, MME
36prostatic urethra urothelial carcinoma10.4FH, FLCN, MET
37pneumothorax, primary spontaneous10.4FH, FLCN, MET
38seminal vesicle adenocarcinoma10.4KIT, MME
39follicular basal cell carcinoma10.4KIT, KRT7
40pediatric ovarian dysgerminoma10.4AMACR, MME, PAX8
41aortitis10.4AMACR, KRT7, PRCC
42diffuse pulmonary fibrosis10.4KIT, MME
43wdha syndrome10.3KIT, KRT7
44acquired hemangioma10.3CA9, KRT7
45hereditary renal cell carcinoma10.3ASPSCR1, MITF, PRCC, TFE3
46breast cancer10.3
47taylor's syndrome10.3AMACR, KRT7, PAX8
48spermatogenic failure 1310.3KIT, KRT7, MET
49esophagus adenocarcinoma10.3AMACR, PAX8
50tenosynovitis of foot and ankle10.3KIT, KRT7, MET

Graphical network of the top 20 diseases related to Renal Cell Carcinoma, Papillary:



Diseases related to renal cell carcinoma, papillary

Symptoms for Renal Cell Carcinoma, Papillary

About this section


Clinical features from OMIM:

605074,300854

HPO human phenotypes related to Renal Cell Carcinoma, Papillary:

id Description Frequency HPO Source Accession
1 papillary renal cell carcinoma HP:0006766
2 renal cell carcinoma HP:0005584

Drugs & Therapeutics for Renal Cell Carcinoma, Papillary

About this section

Drugs for Renal Cell Carcinoma, Papillary (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 443)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Sunitinibapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1486341031-54-7, 557795-19-45329102
Synonyms:
(2S)-2-hydroxybutanedioic acid
1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1)
1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1)
326914-13-0
341031-54-7
5-(5-FLUORO-2-OXO-1,2-DIHYDRO-INDOL-3-YLIDENEMETHYL)-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXYLIC ACID (2-DIETHYLAMINO-ETHYL)-AMIDE
557795-19-4
AC1NS62J
AC1O5CMQ
AKOS005145765
Butanedioic acid, hydroxy-, (2S)-, compd. with N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (1:1)
CHEBI:38940
CHEBI:550864
CHEMBL1567
CHEMBL535
CID5329102
CID6456015
D06402
D08552
DB01268
DB07417
EN002687
FT-0083555
FT-0083556
I01-1229
K00588a
KS-5022
LS-186078
LS-187023
LS-187648
MolPort-003-986-763
N-(2-(Diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (2S)-hydroxybutanedioate
N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
NCGC00164631-01
 
NSC736511
NSC750690
PDGF TK antagonist
PHA-290940AD
PNU-290940AD
S1042_Selleck
ST51053712
SU 011248
SU 11248
SU-010398
SU-011248 L-malate salt
SU-11248
SU-11248 L-malate salt
SU-11248J
SU-12662
SU010398
SU011248
SU011248 L-malate salt
SU11248
Su-011248
Sunitanib
Sunitinib
Sunitinib (INN)
Sunitinib (free base)
Sunitinib Malate
Sunitinib malate
Sunitinib malate (JAN/USAN)
Sunitinib malate [USAN]
Sunitinibum
Sutent
Sutent (TN)
Sutent, SU-11248
TL8002546
UNII-LVX8N1UT73
UNII-V99T50803M
sunitinib
sunitinibum
2
Midazolamapproved, illicitPhase 4, Phase 163559467-70-84192
Synonyms:
4H-Imidazo[1,5-a][1,4]benzodiazepine, 8-chloro-6-(2-fluoro-phenyl)-1-methyl-, (Z)-2-butenedioate
59467-70-8
8-Chlor-6-(2-fluorphenyl)-1-methyl-4H-imidazo(1,5-a)(1,4)benzodiazepin
8-Chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]benzodiazepine
8-Chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5a][1,4]benzodiazepine hydrochloride
8-Chloro-6-(O-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]-benzodiazepine
8-Chloro-6-(o-fluorophenyl)-1-methyl-4H-imidazo(1,5-a)(1,4)benzodiazepine
AC-18749
AC1L1HMA
BIDD:GT0647
BRN 0625572
Buccolam
C07524
C18H13ClFN3
CHEMBL655
CID4192
D00550
DB00683
DEA No. 2884
Dazolam
Dea No. 2884
Dormicum
 
Dormicum (TN)
EINECS 261-774-5
LS-77780
Midanium
Midazolam
Midazolam (JAN/INN)
Midazolam Base
Midazolam Hcl
Midazolam Hydrochloride
Midazolam [INN:BAN:JAN]
Midazolamum
Midazolamum [INN-Latin]
Midosed
MolPort-003-849-219
NCGC00168254-01
Ro 21-3981
TL8003787
UC429_SIGMA
UNII-R60L0SM5BC
Versed
ZINC00001732
midazolam
nchembio747-comp32
3
AldesleukinapprovedPhase 4, Phase 3, Phase 2, Phase 1, Phase 038785898-30-2
Synonyms:
IL-2
Interleukin-2 precursor
 
Proleukin
T-cell growth factor
TCGF
4
NicotineapprovedPhase 497354-11-5942, 89594
Synonyms:
(−
(+)-Nicotine
(+-)-3-(1-Methyl-2-pyrrolidinyl)pyridine
(+-)-Nicotine
(-)-3-(1-Methyl-2-pyrrolidyl)pyridine
(-)-3-(N-Methylpyrrolidino)pyridine
(-)-Nicotine
(-)-Nicotine solution
(2S) 3-(1-Methyl-pyrrolidin-2-yl)-pyridine
(R)-3-(1-Methyl-2-pyrrolidinyl)pyridine
(R,S)-Nicotine
(R,S)-nicotine
(RS)-nicotine
(S)-(-)-NICOTINE, 3-[(2S)-1-METHYL-2-PYRROLIDINYL] PYRIDINE
(S)-(-)-Nicotine
(S)-3-(1-methylpyrrolidin-2-yl)pyridine
(S)-3-(N-methylpyrrolidin-2-yl)pyridine
(S)-Nicotine
(±)-nicotine
)-1-Methyl-2-(3-pyridyl)pyrrolidine
)-Nicotine
)-Nicotine solution
1-Methyl-2-(3-pyridal)-Pyrrolidine
1-Methyl-2-(3-pyridal)-pyrrolidene
1-Methyl-2-(3-pyridiyl)pyrrolidine
1-Methyl-2-(3-pyridyl)pyrrolidine
1uw6
2'-beta-H-Nicotine
3-(1-Methyl-2-pyrollidinyl)pyridine
3-(1-Methyl-2-pyrrolidinyl)-Pyridine
3-(1-Methyl-2-pyrrolidinyl)pyridine
3-(1-Methylpyrrolidin-2-yl)pyridine
3-(2-(N-methylpyrrolidinyl))pyridine
3-(N-Methylpyrollidino)pyridine
3-(N-Methylpyrrolidino)pyridine
3-N-Methylpyrrolidine
3-[(2S)-1-methylpyrrolidin-2-yl]pyridine
36733_FLUKA
36733_RIEDEL
434F7990-3240-4A43-ACEC-E6CC1E495FA0
46343_FLUKA
46343_RIEDEL
54-11-5
AC1L3I79
AC1Q3ZOC
AI3-03424
American Fare Nicotine Transdermal System
BB_NC-0777
BIDD:GT0599
BRD-K05395900-322-02-1
Black Leaf
Black Leaf 40
C00745
CCRIS 1637
CHEBI:17688
CHEMBL3
CID89594
CPD000059074
Campbell's Nico-Soap
Careone Nicotine Transdermal System Step 1
Careone Nicotine Transdermal System Step 2
Careone Nicotine Transdermal System Step 3
Caswell No. 597
Commit
D-Nicotine
D03365
DL-tetrahydronicotyrine
Destruxol
Destruxol Orchid Spray
EINECS 200-193-3
ENT 3,424
EPA Pesticide Chemical Code 056702
Emo-Nik
Equaline Nicotine Transdermal System STEP 1
Exchange Select Nicotine Transdermal System STEP 3
Flux Maag
Fumeto bac
Fumetobac
HSDB 1107
Habitrol
Habitrol (TN)
Habitrol Patch Nicotine Transdermal System, Step 1
Habitrol Patch Nicotine Transdermal System, Step 2
Habitrol Patch Nicotine Transdermal System, Step 3
Healthmart Nicotine Transdermal System STEP 1
Healthmart Nicotine Transdermal System STEP 2
Healthmart Nicotine Transdermal System STEP 3
Kroger Nicotine Transdermal System STEP 1
Kroger Nicotine Transdermal System STEP 2
Kroger Nicotine Transdermal System STEP 3
L(-)-nicotine
L-3-(1-Methyl-2-pyrrolidyl)pyridine
L-Nicotine
LS-202
Leader Nicotine
Leader Nicotine Transdermal System STEP 1
Leader Nicotine Transdermal System STEP 2
Leader Nicotine Transdermal System STEP 3
MLS001055457
 
MLS001335905
Mach-Nic
Meijer Nicotine Transdermal System STEP 2
Meijer Nicotine Transdermal System Step 1
Meijer Nicotine Transdermal System Step 3
Methyl-2-pyrrolidinyl)pyridine
Micotine
MolPort-000-744-731
N3876_SIGMA
N5511_FLUKA
N5511_SIGMA
NCGC00090693-01
NCGC00090693-02
NCGC00090693-03
NCGC00090693-04
NCGC00090693-05
NCGC00090693-06
NCGC00090693-07
NCT
NICOTINE AND SALTS
NSC 5065
NSC97238
Niagara P.A. Dust
Nic-Sal
Nico-Dust
Nico-Fume
Nicocide
Nicoderm
Nicoderm CQ
Nicoderm Cq
Nicoderm Patch
Nicorette
Nicorette Plus
Nicotin
Nicotina
Nicotina [Italian]
Nicotine
Nicotine (USP)
Nicotine (compounds related to)
Nicotine Alkaloid
Nicotine Patch
Nicotine Polacrilex
Nicotine TRANSDERMAL SYSTEM
Nicotine Transdermal System PATCH KIT
Nicotine Transdermal System STEP 1
Nicotine Transdermal System STEP 2
Nicotine Transdermal System STEP 3
Nicotine Transdermal System Step 1
Nicotine Transdermal System Step 2
Nicotine Transdermal System Step 3
Nicotine [BSI:ISO]
Nicotine [UN1654]
Nicotine [UN1654] [Poison]
Nicotine [USAN]
Nicotine transdermal system
Nicotrol
Nicotrol (professional Sample)
Nicotrol Inhaler
Nicotrol Ns
Nictoine patch
Nikotin
Nikotin [German]
Nikotyna
Nikotyna [Polish]
Ortho N-4 Dust
Ortho N-5 Dust
PDSP1_000113
PDSP1_000465
PDSP2_000463
PDSP2_000555
Prostep
R)-(+)-Nicotine
RCRA waste no. P075
RCRA waste number P075
Rite Aid Nicotine Transdermal System Step 1
Rite Aid Nicotine Transdermal System Step 2
Rite Aid Nicotine Transdermal System Step 3
SAM002564224
SDCCGMLS-0066911.P001
SMR000059074
Safeway Nicotine Transdermal System STEP 1
Safeway Nicotine Transdermal System STEP 2
Safeway Nicotine Transdermal System STEP 3
Smart Sense Nicotine
Sunmark Nicotine
Sunmark Nicotine Transdermal System STEP 1
Sunmark Nicotine Transdermal System STEP 2
Sunmark Nicotine Transdermal System STEP 3
Tendust
Transdermal Nicotine
UN1654
a -N-Methylpyrrolidine
a-N-Methylpyrrolidine
alpha-N-Methylpyrrolidine
beta-Pyridyl-alpha-N-methyl pyrrolidine
beta-Pyridyl-alpha-N-methylpyrrolidine
bmse000105
delta-Nicotine
nicotine
nicotine replacement patch
5
Sirolimusapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1179753123-88-95284616, 6436030, 46835353
Synonyms:
(-)-Rapamycin
(-)-rapamycin
1fkb
1pbk
23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine
23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine
23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29
3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
53123-88-9
A422989, NSC226080
AC-722
AC1L1JH9
AC1L7MJ9
AC1L9ZMV
AY 22989
AY-22989
AY22989
Ambotz53123-88-9
Antibiotic AY 22989
BIDD:PXR0165
Bio1_000293
Bio1_000782
Bio1_001271
Bio2_000375
Bio2_000855
BiomolKI2_000084
C07909
C51H79NO13
CBiol_002007
CCRIS 9024
CHEBI:100923
CHEBI:9168
CHEMBL413
CID10213190
CID10795871
CID11949238
CID11959112
CID313006
CID478951
CID5040
CID5284616
CID5358081
CID5374464
CID5460439
CID5497196
CID5924240
CID6436030
CID6610270
CID6610346
CID6711160
CID6713081
CID9833581
CID9854379
CID9854380
CID9962926
CID9962928
D00753
DB00877
DE-109
DivK1c_006936
 
FT-0082351
HMS2089A21
HSDB 7284
KBio1_001880
KBio2_000410
KBio2_002978
KBio2_005546
KBio3_000779
KBio3_000780
KBioGR_000410
KBioSS_000410
LCP-Siro
LMPK06000003
LS-143290
MLS000028373
MS-R001
MolMap_000043
MolPort-003-959-433
NCGC00021305-05
NCI60_001851
NCIMech_000355
NSC 226080
NSC226080
Perceiva
QTL1_000069
R0395_SIAL
R0395_SIGMA
RAP
RAPA
RPM
Rapammune
Rapamune
Rapamune (TN)
Rapamycin
Rapamycin (TN)
Rapamycin C-7, analog 4
Rapamycin Immunosuppressant Drug
Rapamycin from Streptomyces hygroscopicus
S1039_Selleck
SIIA 9268A
SILA 9268A
SILA9268A
SMP1_000255
SMR000058564
Sirolimus
Sirolimus (RAPAMUNE)
Sirolimus (USAN/INN)
Sirolimus [USAN:BAN:INN]
Sirolimus, Rapamune,Rapamycin
SpecPlus_000840
UNII-W36ZG6FT64
UNM-0000358684
WY-090217
Wy 090217
heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy
nchembio.100-comp4
nchembio.2007.42-comp2
nchembio.79-comp1
nchembio762-comp1
nchembio883-comp3
rapamycin
sirolimus
6
DexmedetomidineapprovedPhase 4470113775-47-668602, 5311068, 56032
Synonyms:
(+)-4-((S)-alpha,2,3-Trimethylbenzyl)imidazole
(+)-4-((S)-alpha,2,3-trimethylbenzyl)imidazole
(+)-medetomidine
(S)-medetomidine
113775-47-6
4-[(1S)-1-(2,3-Dimethylphenyl)ethyl]-1H-imidazole
4-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1H-imidazole
5-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1H-imidazole
AC1NSJXT
C07450
CHEBI:4466
CHEMBL778
CID5311068
D00514
DEXMEDETOMIDINE
Dexdor (T)
 
Dexmedetomidin
Dexmedetomidina
Dexmedetomidine
Dexmedetomidine (USAN/INN)
Dexmedetomidine Hydrochloride
Dexmedetomidinum
Dexmédétomidine
MPV 1440
MPV-1440
Medetomidina [Spanish]
Medetomidine
Medetomidinum [Latin]
NCGC00025347-01
PRECEDEX
Precedex
Precedex (TN)
Tocris-2023
ZINC04632106
7
Sorafenibapproved, investigationalPhase 4, Phase 3, Phase 1, Phase 2671284461-73-0216239, 406563
Synonyms:
284461-73-0
4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide
4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide
4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate
4-(4-{3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide
4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide
4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide
4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide
4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide
4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE
AB1004622
AC-1674
AC1L50CF
BAX
BAY 43-9006
BAY 43-9006 (free base)
BAY 43-9006 tosylate salt
BAY 439006
BAY 54-9085 (tosylate salt)
BAY-43-0006
BAY-43-9006
BAY-54-9085
BAY43-9006
BRD-K23984367-001-01-8
Bio-0100
CHEBI:47228
CHEBI:50924
CHEMBL1336
CID216239
 
D08524
DB00398
DB07438
EN002709
I06-0856
K00597a
Kinome_766
LS-186067
LS-187021
LS-187788
MolPort-003-850-270
N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea
N-(4-Chloro-3-(trifluoromethyl)phenyl)-n'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea
N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea
N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea
NCGC00167488-01
NSC-724772
NSC747971
Nexavar
STK627350
Sorafenib
Sorafenib (INN)
Sorafenib Tosylate
Sorafenib [INN]
Sorafenib tosylate
Sorafenibum
UNII-9ZOQ3TZI87
ZINC01493878
nchembio.117-comp17
sorafenib
sorafenibum
8
NivolumabapprovedPhase 4, Phase 3, Phase 2, Phase 1198946414-94-4
Synonyms:
BMS-936558
 
MDX-1106
ONO-4538
nivolumab
9
Axitinibapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1100319460-85-06450551
Synonyms:
319460-85-0
790713-39-2
AC-1539
AC1O51X3
AG 013736
AG-013736
AG-013736, Axitinib
AG-13736
AG013736
Axitinib
C503983
CID6450551
 
EC-000.2322
I14-1971
INLYTA
Inlyta
MolPort-006-392-413
N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide
N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide
S1005_Selleck
SID103905539
ST51054130
UNII-C9LVQ0YUXG
ZINC03816287
axitinib
10
Miconazoleapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1302622916-47-84189
Synonyms:
(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole
1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole
1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
22832-87-7 (NITRATE)
22916-47-8
75319-47-0
AB00053500
AC1L1HM1
AKOS001574474
Aflorix(nitrate)
Albistat(nitrate)
Andergin(nitrate)
BPBio1_000279
BRD-A82396632-001-03-0
BRD-A82396632-008-02-7
BRN 0965511
BSPBio_000253
BSPBio_002033
CCRIS 7924
CHEBI:6923
CHEMBL91
CID4189
CPD-4501
Conofite(nitrate)
D00416
DB01110
Dactarin
Daktarin IV
Daktarin iv
Desenex
DivK1c_000156
EINECS 245-324-5
Epi-Monistat(nitrate)
Femizol-M
Florid(nitrate)
Gyno-Daktar(nitrate)
HMS1568M15
HMS2090B21
I14-14342
IDI1_000156
Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)
KBio1_000156
KBio2_001445
KBio2_004013
KBio2_006581
KBio3_001533
KBioGR_000581
KBioSS_001445
LS-78378
Lotrimin AF(nitrate)
MCZ
MJR 1762
MLS002222203
Makesense
Micantin (nitrate)
Micatin
 
Miconasil Nitrate
Miconazol
Miconazol [INN-Spanish]
Miconazole
Miconazole (JP15/USP/INN)
Miconazole 3
Miconazole 3 Combination Pack
Miconazole 7 Combination Pack
Miconazole [USAN:BAN:INN:JAN]
Miconazole nitrate salt
Miconazole-7
Miconazolo
Miconazolo [DCIT]
Miconazolum
Miconazolum [INN-Latin]
Micozole
Minostate
MolPort-002-557-553
Monazole 7
Monista (nitrate)
Monistat
Monistat (TN)
Monistat 1 Combination Pack
Monistat 3 Dual-Pak
Monistat 3 Vaginal Ovules
Monistat 5 Tampon
Monistat 7 Dual-Pak
Monistat 7 Vaginal Suppositories
Monistat Dual- PAK
Monistat IV
Monistat iv (TN)
Monistat iv (tn)
Monistat-Derm
NCI60_001353
NCI60_001380
NINDS_000156
NSC 170986
NSC169434
NSC170986
Novo-Miconazole Vaginal Ovules
Oprea1_091955
Oravig
Prestwick0_000067
Prestwick1_000067
Prestwick2_000067
Prestwick3_000067
Prestwick_335
R 18134
R-14,889
Rash Relief Antifungal
SMR001307249
SPBio_000976
SPBio_002174
STK834405
STOCK1S-93556
Spectrum2_001048
Spectrum3_000507
Spectrum4_000061
Spectrum5_001297
Spectrum_000965
UNII-7NNO0D7S5M
Vusion
Zimycan
imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)
miconazole
11
GemcitabineapprovedPhase 4, Phase 2, Phase 1188195058-81-460750
Synonyms:
103882-84-4
122111-03-9
2',2'-DiF-dC
2',2'-Difluoro-2'-deoxycytidine
2',2'-Difluorodeoxycytidine
2'-Deoxy-.beta.-D-2',2'-difluorocytidine
2'-Deoxy-2',2'-difluorocytidine
4-Amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
4-Amino-1-[3,3-difluoro-4-hydroxy-5-(hydroxymethyl) tetrahydrofuran-2-yl]-1H-pyrimidin-2-one
4-amino-1-((2R,4R,5R)-3,3-Difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
95058-81-4
AB1004842
AC1L1TUQ
C07650
CCRIS 8984
CHEBI:175901
CHEMBL888
CID60750
Cytidine, 2'-deoxy-2',2'-difluoro-2'-Deoxy-.beta.-D-2',2'-difluorocytidine
D02368
DB00441
DDFC
DFDC
DFdC
DFdCyd
Folfugem
GEO
Gamcitabine
GemLip
Gemcel
 
Gemcin
Gemcitabin
Gemcitabina
Gemcitabina [INN-Spanish]
Gemcitabine
Gemcitabine (USAN/INN)
Gemcitabine HCl
Gemcitabine Hydrochloride
Gemcitabine hydrochloride
Gemcitabine stereoisomer
Gemcitabinum
Gemcitabinum [INN-Latin]
Gemtro
Gemzar
Gemzar (hydrochloride)
HMS2089P10
HSDB 7567
Inno-D07001
LS-59139
LY 188011
LY-188011
LY188011
NCGC00168784-01
NChemBio.2007.10-comp25
NSC 613327
NSC613327
TL8005979
UNII-B76N6SBZ8R
ZINC18279854
Zefei
gemcitabine
nchembio.573-comp7
nchembio.90-comp2
12
EverolimusapprovedPhase 4, Phase 3, Phase 2, Phase 11797159351-69-66442177
Synonyms:
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,23S,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriacont
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34as)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethy
07741_FLUKA
159351-69-6
40-O-(2-hydroxyethyl)-rapamycin
42-O-(2-Hydroxyethyl)rapamycin
Afinitor
Afinitor Disperz
CERTICAN(R)
CHEMBL1201755
Certican
D02714
DB01590
 
Everolimus
Everolimus (JAN/USAN/INN)
Everolimus [USAN]
LS-143292
MolPort-003-847-342
MolPort-003-925-588
NCGC00167512-01
NVP-RAD-001
RAD 001
RAD-001
RAD-001C
RAD001
RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus
S1120_Selleck
SDZ-RAD
UNII-9HW64Q8G6G
VOTUBIA
Zortress
everolimus
13
Bevacizumabapproved, investigationalPhase 4, Phase 3, Phase 1, Phase 21875216974-75-3
Synonyms:
216974-75-3
Avastin
Avastin (TN)
Bevacizumab
Bevacizumab (genetical recombination)
 
Bevacizumab (genetical recombination) (JAN)
D06409
R-435
anti-VEGF monoclonal antibody
antiVEGF
bevacizumab
14
Caffeineapproved, NutraceuticalPhase 433958-08-22519
Synonyms:
07E4FB58-FD79-4175-8E3D-05BF96954522
1,3,7-Trimethyl-2,6-dioxopurine
1,3,7-Trimethyl-3,7-dihydro-1H-purine-2,6-dione
1,3,7-Trimethylpurine-2,6-dione
1,3,7-Trimethylxanthine
1,3,7-trimethylpurine-2,6-dione
1,3,7-trimethylxanthine
1-3-7-TRIMETHYLXANTHINE
1-Methyl-Theobromine
1-methyltheobromine
137X
1gfz
1l5q
1l7x
27602_FLUKA
2a3b
3,7-Dihydro-1,3,7-trimethyl-1H-purin-2,6-dion
3,7-Dihydro-1,3,7-trimethyl-1H-purine-2,6-dione
3,7-dihydro-1,3,7-trimethyl-1H-purine
5-26-13-00558 (Beilstein)
58-08-2
7-Methyl Theophylline
7-Methyltheophylline
7-methyltheophylline
71701-02-5
75035_FLUKA
95789-13-2
A.S.A. and Codeine Compound
AC-12774
AC1L1DV2
AC1Q3Z23
ACon1_000085
AI3-20154
AKOS000121334
Alert
Alert-Pep
Alert-pep
Allertness Aid
Anacin Maximum Strength
Anhydrous caffeine
Anhydrous caffeine (JP15)
Anhydrous caffeine (TN)
Anoquan
Awake
BIDD:ER0554
BIDD:GT0632
BIDD:PXR0172
BIM-0050216.0001
BRD-K02404261-001-02-7
BRD-K02404261-001-03-5
BRN 0017705
BSPBio_001921
Berlin-Chemie Brand of Caffeine
Bio-0579
Bio1_000473
Bio1_000962
Bio1_001451
Bristol-Myers Squibb Brand of Caffeine
C 0750
C07481
C0750_SIAL
C1778_SIAL
C2042
C6035_FLUKA
C6035_SIGMA
C7731_SIAL
C8960_SIAL
CCRIS 1314
CFF
CHEBI:27732
CHEMBL113
CID2519
CU-01000012617-3
Cafamil
Cafcit
Cafecon
Cafeina
Cafergot
Cafeína
Caffedrine
Caffedrine Caplets
Caffein
Caffeina
Caffeina [Italian]
Caffeine
Caffeine (USP)
Caffeine (natural)
Caffeine Citrate
Caffeine Pure
Caffeine [BAN:JAN]
Caffeine citrate
Caffeine solution
Caffeine, Anhydrous
Caffeine, Monohydrate
Caffeine, Synthetic
Caffeine, anhydrous
Caffeine, synthetic
Caffine
Cafipel
Caféine
Circle K Nosnooze
Coffein
Coffein [German]
Coffeine
Coffeinum
Coffeinum N
Coffeinum Purrum
Compound 65
Conrx Alert
D002110
D00528
DB00201
DHC Plus
DHCplus
Darvon Compound
Darvon Compound-65
Dasin
Dexitac
Dexitac Stay Alert Stimulant
Dhc Plus
Diurex
Diurex Ultra
Diurex WaterCaps
DivK1c_000730
Drowz Away Maximum strength
Durvitan
EINECS 200-362-1
EU-0100228
Eldiatric C
Enerjets
Equaline Stay Awake
Ercatab
Esgic
Esgic-Plus
FEMA No. 2224
Femcet
Fioricet
Fiorinal
GlaxoSmithKline Brand of Caffeine
Good Neighbor Pharmacy Stay Awake
Good Sense Stay Awake
Guaranine
HMS1920I09
HMS2091O11
HMS502E12
HSDB 36
Health Mart Stay Awake
Healthy Accents Stay Awake
Hycomine
Hycomine Compound
I14-4386
IDI1_000730
 
Invagesic
Invagesic Forte
KBio1_000730
KBio2_001781
KBio2_004349
KBio2_006917
KBio3_001141
KBioGR_002325
KBioSS_001781
Keep Alert
Kofein
Kofein [Czech]
Koffein
Koffein [German]
L000155
LS-237
Lanorinal
Leader Alertness Aid
Lil Drug Store Nosnooze
Lopac-C-0750
Lopac0_000228
MEGxp0_001350
MLS001055341
MLS001056714
MLS001066409
Mateina
Mateína
Maximum Strength Caffeine
Maximum Strength Snapback Stimulant Powders
Maximum Strength Stay Awake
Medigesic Plus
Merck dura Brand of Caffeine
Methyltheobromide
Methyltheobromine
Methylxanthine theophylline
Midol Maximum Strength
Migergot
Miudol
MolMap_000054
MolPort-000-730-850
Monohydrate Caffeine
Monomethyl Derivative of Theophylline
Monomethyl derivative of Theophylline
NCGC00015208-01
NCGC00015208-02
NCGC00015208-04
NCGC00015208-14
NCGC00090699-01
NCGC00090699-02
NCGC00090699-03
NCGC00090699-04
NCGC00090699-05
NCGC00090699-06
NCGC00090699-07
NCGC00090699-08
NCGC00090699-09
NCGC00168808-01
NCGC00168808-02
NCI-C02733
NCIOpen2_008255
NINDS_000730
NSC 5036
NSC5036
Nano Ppc
Natural Caffeinum
Nix Nap
No Doz
No-Doz
Nodaca
Nodoz Maximum Strength Caplets
Norgesic
Norgesic Forte
Organex
Orphengesic
Orphengesic Forte
P-A-C Analgesic Tablets
PDSP1_001016
PDSP1_001235
PDSP2_001000
PDSP2_001219
Passauer Brand of Caffeine
Pep-Back
Pep-back Peak Performance
Pep-back Ultra
Percoffedrinol N
Percutafeine
Phensal
Pierre Fabre Brand of Caffeine
Probes1_000150
Probes2_000128
Propoxyphene
Propoxyphene Compound 65
Propoxyphene Compound-65
Quick Pep
Quick-Pep
Refresh'n
Republic Drug Brand of Caffeine
SDCCGMLS-0064595.P001
SDCCGMLS-0064595.P002
SK 65 Compound
SK-65 Compound
SMR000326667
SPBio_001222
SPECTRUM1500155
STK177283
Seid Brand of Caffeine
Smart Sense Stay Awake
Sohmed Alertness Aid
Spectrum2_001261
Spectrum3_000321
Spectrum4_001782
Spectrum5_000423
Spectrum_001301
Stay Alert Aid
Stay Awake
Stay Awake Maximum Strength
Stay Awake Maximum strength
Stim
Sunmark Stay Awake
Synalgos-Dc
TNP00310
Teina
Thein
Theine
Theobromine ME
Theobromine Me
Theophylline ME
Theophylline Me
Theophylline, 7-methyl
Thompson Brand 1 of Caffeine
Thompson Brand 2 of Caffeine
Tirend
Topcare Stay Awake maximum strength
Tri-Aqua
Triad
UNII-3G6A5W338E
Ultra Pep-Back
Vivarin
W222402_ALDRICH
WLN: T56 BN DN FNVNVJ B1 F1 H1
Wake-Up
Wigraine
Xanthine, 1,3,7-trimethyl
ZINC00001084
bmse000206
cafeine
caffeine
caffenium
component of Cafergot
nchembio.243-comp7
nchembio.63-comp5
nchembio774-comp2
teina
15Adrenergic AgentsPhase 44204
16Adrenergic AgonistsPhase 42331
17Nicotinic AgonistsPhase 4701
18Adrenergic alpha-2 Receptor AgonistsPhase 4790
19Anti-Infective AgentsPhase 4, Phase 3, Phase 2, Phase 117220
20Central Nervous System StimulantsPhase 41721
21Liver ExtractsPhase 4, Phase 3, Phase 2, Phase 1, Phase 03572
22Adrenergic alpha-AgonistsPhase 41300
23Cholinergic AgentsPhase 4, Phase 23243
24Antibiotics, AntitubercularPhase 4, Phase 3, Phase 2, Phase 15971
25Interferon-alphaPhase 4, Phase 3, Phase 2, Phase 11028
26Imatinib MesylatePhase 4, Phase 2, Phase 1577123596
27interferonsPhase 4, Phase 3, Phase 2, Phase 11930
28Angiogenesis InhibitorsPhase 4, Phase 3, Phase 1, Phase 23688
29Angiogenesis Modulating AgentsPhase 4, Phase 3, Phase 1, Phase 23611
30Antiviral AgentsPhase 4, Phase 3, Phase 2, Phase 18071
31Tranquilizing AgentsPhase 43597
32Anti-Bacterial AgentsPhase 4, Phase 3, Phase 2, Phase 19140
33AntimetabolitesPhase 4, Phase 3, Phase 2, Phase 19454
34Antimetabolites, AntineoplasticPhase 4, Phase 3, Phase 2, Phase 15770
35Antifungal AgentsPhase 4, Phase 3, Phase 2, Phase 13015
36HormonesPhase 4, Phase 2, Phase 1, Phase 011748
37Peripheral Nervous System AgentsPhase 4, Phase 3, Phase 2, Phase 1, Phase 018510
38Bone Density Conservation AgentsPhase 4, Phase 1, Phase 22600
39DiphosphonatesPhase 4, Phase 1, Phase 2381
40
Zoledronic acidPhase 4, Phase 1, Phase 2286118072-93-868740
Synonyms:
(1-Hydroxy-2-imidazol-1-ylethylidene)diphosphonic acid
(1-hydroxy-2-(1H-imidazol-1-yl)ethylidene)bisphosphonic acid
(1-hydroxy-2-imidazol-1-yl-1-phosphonoethyl)phosphonic acid
(1-hydroxy-2-imidazol-1-yl-phosphonoethyl)phosphonic acid monohydrate
118072-93-8
2-(imidazol-1-yl)-1-hydroxyethane-1,1-diphosphonic acid
2-(imidazol-1-yl)-1-hydroxyethylidene-1,1-bisphosphonic acid
AC-1092
AC1L2ACJ
AC1Q6RN3
AKOS005145739
Aclasta
BIDD:GT0292
BIDD:PXR0134
Bio-0112
Bisphosphonate 3
C088658
CGP 42'446
CGP 42446
CGP 42446A
CGP-42'446
CGP-42446
CHEBI:46557
CHEMBL924
CID68740
D08689
 
DB00399
FT-0082657
HMS2089O09
I06-0710
KS-1132
LS-181815
MolPort-002-885-874
MolPort-003-850-890
NCGC00159521-02
NCGC00159521-03
NSC721517
Novartis brand of zoledronic acid
Reclast
Reclast (TN)
S00092
S1314_Selleck
UNII-70HZ18PH24
ZOL
Zoledronate
Zoledronic acid
Zoledronic acid (INN)
Zoledronic acid [USAN:INN]
Zometa
Zometa (Novartis)
Zometa (TN)
Zometa Concentrate
Zometa, Zomera, Aclasta and Reclast, Zoledronic Acid
[1-hydroxy-2-(1H-imidazol-1-yl)ethane-1,1-diyl]bis(phosphonic acid)
41Psychotropic DrugsPhase 4, Phase 25501
42Interleukin-2Phase 4, Phase 3, Phase 2, Phase 1, Phase 0487
43Immunologic FactorsPhase 4, Phase 3, Phase 2, Phase 118483
44AnalgesicsPhase 4, Phase 3, Phase 2, Phase 1, Phase 09358
45Analgesics, Non-NarcoticPhase 4, Phase 3, Phase 2, Phase 1, Phase 05184
46Immunosuppressive AgentsPhase 4, Phase 3, Phase 2, Phase 110422
47AnestheticsPhase 4, Phase 3, Phase 27385
48Anesthetics, GeneralPhase 4, Phase 32274
49Neurotransmitter AgentsPhase 4, Phase 214795
50Pharmaceutical SolutionsPhase 4, Phase 2, Phase 3, Phase 17004

Interventional clinical trials:

(show top 50)    (show all 1273)
idNameStatusNCT IDPhase
1Everolimus in Patients With Metastatic Renal Cell Carcinoma Following Progression on Prior Bevacizumab TreatmentCompletedNCT02056587Phase 4
2SUTENT® In The First Line Treatment Of Renal Cell CarcinomaCompletedNCT00460798Phase 4
3Interleukin-2 in Treating Patients With Metastatic Kidney CancerCompletedNCT00006864Phase 4
4Effect of Zoledronic Acid in Patients With Renal Cell Cancer and Bone MetastasisCompletedNCT00172003Phase 4
5Retrospective Analysis Of Progression Free Survival And Overall Survival In A National Cohort Of Patients With Metastatic Renal Cell Carcinoma Treated In Denmark From 2006-2010. DARENCA Study 2.CompletedNCT01339962Phase 4
6Safety And Efficacy Study Of Sunitinib Malate As First-Line Systemic Therapy In Chinese Patients With Metastatic Renal Cell CarcinomaCompletedNCT00706706Phase 4
7Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer PatientsCompletedNCT01402089Phase 4
8Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit SmokingCompletedNCT00365508Phase 4
9Effects of Dexmedetomidine During Radiofrequency Ablation of Abdominal TumoursCompletedNCT02016391Phase 4
10A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma.RecruitingNCT01206764Phase 4
11Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or PazopanibRecruitingNCT01514448Phase 4
12Axitinib in Metastatic Renal Cell Carcinoma Patients With Favorable Prognostic FactorsRecruitingNCT02700568Phase 4
13Post Marketing Surveillance for ICE-SENSE™3 a Cryotherapy Treatment of Renal Cell CarcinomaRecruitingNCT02399124Phase 4
14A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Renal Cell CarcinomaRecruitingNCT02596035Phase 4
15First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell CarcinomaRecruitingNCT01521715Phase 4
16Outcome-related Factors in Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus (ORCHIDEE)RecruitingNCT02338570Phase 4
17Evaluation of Predictive Markers for Toxicity and Efficacy in Patients With mccRCC Treated by Anti-VEGF TherapyRecruitingNCT02570789Phase 4
18Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell CarcinomaRecruitingNCT02555748Phase 4
19Study to the Optimal Duration of Therapy With Oral Angiogenesis InhibitorsRecruitingNCT00777504Phase 4
20Open Label, Single Arm Trial to Characterize Patients With Metastatic RCC Treated With Everolimus After Failure of the First VEGF-targeted Therapy (MARC-2)Active, not recruitingNCT01266837Phase 4
21Biological, Pathological and Imagery Markers in the First-line Treatment of Metastatic Clear-cell Renal Cell CarcinomaTerminatedNCT00930345Phase 4
22Phase IV Randomization to On-Going Treatment to Evaluate Sustained SorafenibTerminatedNCT00352859Phase 4
23Cost Effectiveness Of Sunitinib In Central America And CaribbeanTerminatedNCT01033981Phase 4
24Post Marketing Surveillance On The Safety And Tolerability Of Sunitinib Malate (Sutent) For Filipino PatientsTerminatedNCT01073644Phase 4
25Hydroxyethyl Starch and Renal Function After Laparoscopic NephrectomyTerminatedNCT01486550Phase 4
26Study to Observe Safety and Efficacy of Nexavar in Treatment of Kidney CancerWithdrawnNCT01353794Phase 4
27A Post Marketing Surveillance As Required By Philippine Food And Drug AdministrationWithdrawnNCT01781442Phase 4
28Sorafenib in Treating Patients at Risk of Relapse After Undergoing Surgery to Remove Kidney CancerCompletedNCT00492258Phase 3
29TroVax Renal Immunotherapy Survival TrialCompletedNCT00397345Phase 3
30Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer PainCompletedNCT00538850Phase 3
31Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-AntibodyCompletedNCT00606632Phase 3
32Efficacy and Safety of Sorafenib in Advanced Renal Cell Carcinoma (RCC)CompletedNCT00478114Phase 3
33Interferon Alfa With or Without Isotretinoin in Treating Patients With Metastatic Kidney CancerCompletedNCT00002737Phase 3
34Interferon Alfa-2b With or Without Bevacizumab in Treating Patients With Advanced Renal Cell Carcinoma (Kidney Cancer)CompletedNCT00072046Phase 3
35Kidney-Sparing Surgery Compared With Kidney Removal in Treating Patients With Kidney CancerCompletedNCT00002473Phase 3
36AE-941 in Treating Patients With Metastatic Kidney CancerCompletedNCT00005995Phase 3
37Medroxyprogesterone or Interferon and/or Aldesleukin in Treating Patients With Metastatic Kidney CancerCompletedNCT00416429Phase 3
38Interleukin-2 in Treating Patients With Stage III or Stage IV Kidney CancerCompletedNCT00003126Phase 3
39Interleukin-2 in Treating Patients With Metastatic Kidney CancerCompletedNCT00018941Phase 3
40Interleukin-2 and Interferon in Treating Patients With Metastatic Kidney CancerCompletedNCT00416871Phase 3
41Interferon Alfa-2b With or Without Thalidomide in Treating Patients With Metastatic or Unresectable Kidney CancerCompletedNCT00005966Phase 3
42Interleukin-2, Interferon Alfa, and Fluorouracil Compared With Observation in Treating Patients Who Have Undergone Surgery for Kidney CancerCompletedNCT00053807Phase 3
43Interferon Alfa With or Without Interleukin-2 and Fluorouracil in Treating Patients With Advanced Metastatic Kidney CancerCompletedNCT00053820Phase 3
44Survival Study Of Oncophage® vs. Observation In Patients With Kidney CancerCompletedNCT00033904Phase 3
45Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell CarcinomaCompletedNCT01223027Phase 3
46Randomized Study of Spinal Anesthesia Compared With Traditional Epidural Anesthesia Concerning Peroperative and Postoperative Pain After Open Nephrectomy in Patients With Renal Cell CarcinomaCompletedNCT02030717Phase 2, Phase 3
47IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell CarcinomaCompletedNCT01265901Phase 3
48Cytokines in Patients With Metastatic Renal Cell Carcinoma of Intermediate PrognosisCompletedNCT00291369Phase 3
49Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney CancerCompletedNCT00087022Phase 3
50Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma SubjectsCompletedNCT00631371Phase 3

Search NIH Clinical Center for Renal Cell Carcinoma, Papillary

Inferred drug relations via UMLS65/NDF-RT43:


Cochrane evidence based reviews: papillary renal cell carcinoma, sporadic

Genetic Tests for Renal Cell Carcinoma, Papillary

About this section

Genetic tests related to Renal Cell Carcinoma, Papillary:

id Genetic test Affiliating Genes
1 Papillary Renal Carcinoma22 MET

Anatomical Context for Renal Cell Carcinoma, Papillary

About this section

MalaCards organs/tissues related to Renal Cell Carcinoma, Papillary:

33
Kidney, Lung, Bone, Brain, Breast, Prostate, Endothelial

Animal Models for Renal Cell Carcinoma, Papillary or affiliated genes

About this section

MGI Mouse Phenotypes related to Renal Cell Carcinoma, Papillary:

38
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053828.4KIT, MET, MITF, PAX8, RFNG, SCHIP1
2MP:00053678.2FH, FLCN, KIT, KRT7, MET, PAX8

Publications for Renal Cell Carcinoma, Papillary

About this section

Articles related to Renal Cell Carcinoma, Papillary:

idTitleAuthorsYear
1
Radiology rounds. Osteopoikilosis. (10540690)
1999

Variations for Renal Cell Carcinoma, Papillary

About this section

UniProtKB/Swiss-Prot genetic disease variations for Renal Cell Carcinoma, Papillary:

67 (show all 15)
id Symbol AA change Variation ID SNP ID
1METp.Met1131ThrVAR_006286
2METp.Val1188LeuVAR_006287
3METp.Leu1195ValVAR_006288
4METp.Val1220IleVAR_006289
5METp.Asp1228AsnVAR_006290
6METp.Asp1228HisVAR_006291
7METp.Tyr1230CysVAR_006292
8METp.Tyr1230HisVAR_006293
9METp.Met1250ThrVAR_006294
10METp.Val1092IleVAR_032485
11METp.His1094LeuVAR_032486
12METp.His1094ArgVAR_032487
13METp.His1094TyrVAR_032488
14METp.His1106AspVAR_032489
15METp.Tyr1230AspVAR_032491

Clinvar genetic disease variations for Renal Cell Carcinoma, Papillary:

5
id Gene Variation Type Significance SNP ID Assembly Location
1METNM_001127500.1(MET): c.3446T> C (p.Met1149Thr)single nucleotide variantPathogenicrs121913668GRCh37Chr 7, 116418881: 116418881
2METNM_001127500.1(MET): c.3616G> T (p.Val1206Leu)single nucleotide variantPathogenicrs121913669GRCh37Chr 7, 116422081: 116422081
3METNM_001127500.1(MET): c.3712G> A (p.Val1238Ile)single nucleotide variantPathogenicrs121913670GRCh37Chr 7, 116423383: 116423383
4METNM_001127500.1(MET): c.3736G> A (p.Asp1246Asn)single nucleotide variantPathogenicrs121913671GRCh37Chr 7, 116423407: 116423407
5METNM_001127500.1(MET): c.3743A> G (p.Tyr1248Cys)single nucleotide variantPathogenicrs121913246GRCh37Chr 7, 116423414: 116423414
6METNM_001127500.1(MET): c.3637C> G (p.Leu1213Val)single nucleotide variantPathogenicrs121913673GRCh37Chr 7, 116422102: 116422102
7METNM_001127500.1(MET): c.3335A> G (p.His1112Arg)single nucleotide variantPathogenicrs121913243GRCh37Chr 7, 116417464: 116417464

Cosmic variations for Renal Cell Carcinoma, Papillary:

7 (show top 50)    (show all 267)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Conf
1COSM3724578METkidney,NS,carcinoma,papillary renal cell carcinoma3
2COSM3724578METkidney,NS,carcinoma,Type 13
3COSM3724578METkidney,NS,carcinoma,papillary renal cell carcinoma3
4COSM3724577METkidney,NS,carcinoma,Type 13
5COSM3724578METkidney,NS,carcinoma,Type 13
6COSM3724578METkidney,NS,carcinoma,papillary renal cell carcinoma3
7COSM3724576METkidney,NS,carcinoma,Type 13
8COSM3724576METkidney,NS,carcinoma,papillary renal cell carcinoma3
9COSM3724578METkidney,NS,carcinoma,Type 13
10COSM3724577METkidney,NS,carcinoma,papillary renal cell carcinoma3
11COSM3724577METkidney,NS,carcinoma,Type 13
12COSM3724575METkidney,NS,carcinoma,Type 13
13COSM3724575METkidney,NS,carcinoma,papillary renal cell carcinoma3
14COSM3724575METkidney,NS,carcinoma,Type 13
15COSM3724575METkidney,NS,carcinoma,papillary renal cell carcinoma3
16COSM3724575METkidney,NS,carcinoma,papillary renal cell carcinoma3
17COSM3724575METkidney,NS,carcinoma,Type 13
18COSM3724577METkidney,NS,carcinoma,papillary renal cell carcinoma3
19COSM3724577METkidney,NS,carcinoma,Type 13
20COSM3724577METkidney,NS,carcinoma,papillary renal cell carcinoma3
21COSM3724576METkidney,NS,carcinoma,papillary renal cell carcinoma3
22COSM3724576METkidney,NS,carcinoma,Type 13
23COSM691METkidney,NS,carcinoma,papillary renal cell carcinoma3
24COSM691METkidney,NS,carcinoma,Type 13
25COSM691METkidney,NS,carcinoma,papillary renal cell carcinoma3
26COSM691METkidney,NS,carcinoma,Type 13
27COSM691METkidney,NS,carcinoma,Type 13
28COSM691METkidney,NS,carcinoma,papillary renal cell carcinoma3
29COSM691METkidney,NS,carcinoma,Type 13
30COSM691METkidney,NS,carcinoma,papillary renal cell carcinoma3
31COSM691METkidney,NS,carcinoma,Type 13
32COSM691METkidney,NS,carcinoma,papillary renal cell carcinoma3
33COSM691METkidney,NS,carcinoma,Type 13
34COSM691METkidney,NS,carcinoma,Type 13
35COSM691METkidney,NS,carcinoma,papillary renal cell carcinoma3
36COSM3724576METkidney,NS,carcinoma,Type 13
37COSM3724576METkidney,NS,carcinoma,papillary renal cell carcinoma3
38COSM691METkidney,NS,carcinoma,papillary renal cell carcinoma3
39COSM691METkidney,NS,carcinoma,Type 13
40COSM691METkidney,NS,carcinoma,papillary renal cell carcinoma3
41COSM691METkidney,NS,carcinoma,Type 13
42COSM691METkidney,NS,carcinoma,papillary renal cell carcinoma3
43COSM3724573METkidney,NS,carcinoma,Type 13
44COSM3724573METkidney,NS,carcinoma,papillary renal cell carcinoma3
45COSM696METkidney,NS,carcinoma,papillary renal cell carcinoma3
46COSM690METkidney,NS,carcinoma,papillary renal cell carcinoma3
47COSM690METkidney,NS,carcinoma,papillary renal cell carcinoma3
48COSM690METkidney,NS,carcinoma,papillary renal cell carcinoma3
49COSM696METkidney,NS,carcinoma,papillary renal cell carcinoma3
50COSM696METkidney,NS,carcinoma,papillary renal cell carcinoma3

Expression for genes affiliated with Renal Cell Carcinoma, Papillary

About this section
LifeMap Discovery
Genes differentially expressed in tissues of Renal Cell Carcinoma, Papillary patients vs. healthy controls: 32 (show all 207)
id Gene Description Tissue Up/Dn Fold Change (log2) P value
1KCNJ1potassium channel, inwardly rectifying subfamily J, member 1Kidney-9.090.000
2FABP1fatty acid binding protein 1, liverKidney-8.850.000
3SLC12A1solute carrier family 12 (sodium/potassium/chloride transporter), member 1Kidney-8.840.000
4CALB1calbindin 1, 28kDaKidney-8.670.000
5SCNN1Gsodium channel, non voltage gated 1 gamma subunitKidney-8.580.000
6ALDOBaldolase B, fructose-bisphosphateKidney-8.530.000
7CLDN8claudin 8Kidney-8.440.000
8HPD4-hydroxyphenylpyruvate dioxygenaseKidney-8.060.000
9MUC15mucin 15, cell surface associatedKidney-7.910.000
10KNG1kininogen 1Kidney-7.820.000
11EGFepidermal growth factorKidney-7.810.000
12FXYD4FXYD domain containing ion transport regulator 4Kidney-7.680.000
13GSTA1glutathione S-transferase alpha 1Kidney-7.610.000
14NPHS2nephrosis 2, idiopathic, steroid-resistant (podocin)Kidney-7.600.000
15G6PCglucose-6-phosphatase, catalytic subunitKidney-7.500.000
16SLC7A13solute carrier family 7 (anionic amino acid transporter), member 13Kidney-7.320.000
17HMGCS23-hydroxy-3-methylglutaryl-CoA synthase 2 (mitochondrial)Kidney-7.220.000
18RALYLRALY RNA binding protein-likeKidney-7.100.000
19HSD11B2hydroxysteroid (11-beta) dehydrogenase 2Kidney-7.080.000
20FAM151Afamily with sequence similarity 151, member AKidney-7.080.000
21DNASE1deoxyribonuclease IKidney-7.000.000
22TMEM52Btransmembrane protein 52BKidney-6.940.000
23KCNJ10potassium channel, inwardly rectifying subfamily J, member 10Kidney-6.930.000
24IRX2iroquois homeobox 2Kidney-6.900.000
25PVALBparvalbuminKidney-6.660.000
26APOC1apolipoprotein C-IKidney+6.640.000
27SLC13A3solute carrier family 13 (sodium-dependent dicarboxylate transporter), member 3Kidney-6.600.000
28SLC26A7solute carrier family 26 (anion exchanger), member 7Kidney-6.510.000
29SLC4A1solute carrier family 4 (anion exchanger), member 1 (Diego blood group)Kidney-6.510.000
30TYRP1tyrosinase-related protein 1Kidney-6.460.000
31UPB1ureidopropionase, betaKidney-6.390.000
32CYP4A11cytochrome P450, family 4, subfamily A, polypeptide 11Kidney-6.380.000
33SOSTsclerostinKidney-6.350.000
34HEPACAM2HEPACAM family member 2Kidney-6.330.000
35UMODuromodulinKidney-6.210.000
36SCNN1Bsodium channel, non voltage gated 1 beta subunitKidney-6.210.000
37SLC22A6solute carrier family 22 (organic anion transporter), member 6Kidney-6.190.000
38GCgroup-specific component (vitamin D binding protein)Kidney-6.190.000
39MFSD4major facilitator superfamily domain containing 4Kidney-6.190.000
40PDE1Aphosphodiesterase 1A, calmodulin-dependentKidney-6.180.002
41GPC5glypican 5Kidney-6.170.000
42SFRP1secreted frizzled-related protein 1Kidney-6.110.000
43MPPED2metallophosphoesterase domain containing 2Kidney-6.070.000
44HS6ST2heparan sulfate 6-O-sulfotransferase 2Kidney-6.060.004
45SLC22A8solute carrier family 22 (organic anion transporter), member 8Kidney-6.040.000
46WNK4WNK lysine deficient protein kinase 4Kidney-6.030.000
47RHCGRh family, C glycoproteinKidney-6.010.000
48CRHBPcorticotropin releasing hormone binding proteinKidney-5.990.000
49EHFets homologous factorKidney-5.980.000
50C16orf89chromosome 16 open reading frame 89Kidney-5.970.000
51DIO1deiodinase, iodothyronine, type IKidney-5.880.000
52PRDM16PR domain containing 16Kidney-5.880.000
53TMEM213transmembrane protein 213Kidney-5.850.000
54PROM2prominin 2Kidney-5.830.000
55RERGLRERG/RAS-likeKidney-5.780.000
56CLIC5chloride intracellular channel 5Kidney-5.770.000
57KCNN3potassium channel, calcium activated intermediate/small conductance subfamily N alpha, member 3Kidney-5.770.000
58TNFAIP6tumor necrosis factor, alpha-induced protein 6Kidney+5.760.001
59TMPRSS2transmembrane protease, serine 2Kidney-5.750.000
60ENPP6ectonucleotide pyrophosphatase/phosphodiesterase 6Kidney-5.690.000
61GAD1glutamate decarboxylase 1 (brain, 67kDa)Kidney-5.680.000
62SLC14A1solute carrier family 14 (urea transporter), member 1 (Kidd blood group)Kidney-5.680.000
63MYH11myosin, heavy chain 11, smooth muscleKidney-5.660.000
64NELL1neural EGFL like 1Kidney-5.630.000
65LOC284578uncharacterized LOC284578Kidney-5.610.000
66ATP6V1G3ATPase, H+ transporting, lysosomal 13kDa, V1 subunit G3Kidney-5.600.000
67MUC20mucin 20, cell surface associatedKidney-5.560.000
68FAM3Bfamily with sequence similarity 3, member BKidney-5.560.000
69TMEM174transmembrane protein 174Kidney-5.550.000
70SLC4A9solute carrier family 4, sodium bicarbonate cotransporter, member 9Kidney-5.550.000
71RASD1RAS, dexamethasone-induced 1Kidney-5.550.000
72ATP6V0A4ATPase, H+ transporting, lysosomal V0 subunit a4Kidney-5.550.000
73SLC5A12solute carrier family 5 (sodium/monocarboxylate cotransporter), member 12Kidney-5.540.001
74SLC22A12solute carrier family 22 (organic anion/urate transporter), member 12Kidney-5.530.000
75C1orf168chromosome 1 open reading frame 168Kidney-5.490.000
76PTGER3prostaglandin E receptor 3 (subtype EP3)Kidney-5.470.000
77SLC12A3solute carrier family 12 (sodium/chloride transporter), member 3Kidney-5.420.000
78TCF21transcription factor 21Kidney-5.410.000
79ESRRBestrogen-related receptor betaKidney-5.410.000
80CYP4A22cytochrome P450, family 4, subfamily A, polypeptide 22Kidney-5.380.000
81ALBalbuminKidney-5.370.000
82CTXN3cortexin 3Kidney-5.370.000
83C2orf40chromosome 2 open reading frame 40Kidney-5.350.000
84HAO2hydroxyacid oxidase 2 (long chain)Kidney-5.320.001
85NOS1nitric oxide synthase 1 (neuronal)Kidney-5.310.000
86EYA4EYA transcriptional coactivator and phosphatase 4Kidney-5.290.001
87PCK1phosphoenolpyruvate carboxykinase 1 (soluble)Kidney-5.290.000
88FABP4fatty acid binding protein 4, adipocyteKidney-5.280.000
89MECOMMDS1 and EVI1 complex locusKidney-5.270.000
90TMEM178Atransmembrane protein 178AKidney-5.260.001
91RENreninKidney-5.260.000
92ZNF44zinc finger protein 44Kidney-5.250.000
93CRYAAcrystallin, alpha AKidney-5.240.000
94SERPINA5serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 5Kidney-5.240.000
95ADH1Balcohol dehydrogenase 1B (class I), beta polypeptideKidney-5.220.000
96FGF9fibroblast growth factor 9Kidney-5.190.000
97RAB25RAB25, member RAS oncogene familyKidney-5.180.000
98UPP2uridine phosphorylase 2Kidney-5.180.001
99AQP2aquaporin 2 (collecting duct)Kidney-5.150.000
100TPCN2two pore segment channel 2Kidney-5.140.000
101NTRK2neurotrophic tyrosine kinase, receptor, type 2Kidney-5.120.001
102ATP6V1B1ATPase, H+ transporting, lysosomal 56/58kDa, V1 subunit B1Kidney-5.110.000
103AFMafaminKidney-5.110.000
104TBX2T-box 2Kidney-5.090.000
105STAP1signal transducing adaptor family member 1Kidney-5.070.000
106RALGAPA2Ral GTPase activating protein, alpha subunit 2 (catalytic)Kidney-5.050.000
107MMEmembrane metallo-endopeptidaseKidney-5.040.002
108AGXTalanine-glyoxylate aminotransferaseKidney-5.040.000
109ERBB4erb-b2 receptor tyrosine kinase 4Kidney-5.040.003
110SLC22A7solute carrier family 22 (organic anion transporter), member 7Kidney-5.040.001
111MT1Gmetallothionein 1GKidney-5.020.000
112TCEAL2transcription elongation factor A (SII)-like 2Kidney-4.990.000
113CYP4F2cytochrome P450, family 4, subfamily F, polypeptide 2Kidney-4.990.000
114XPNPEP2X-prolyl aminopeptidase (aminopeptidase P) 2, membrane-boundKidney-4.990.000
115WT1Wilms tumor 1Kidney-4.990.000
116C7complement component 7Kidney-4.960.000
117LOC285556uncharacterized LOC285556Kidney-4.940.000
118TMEM45Btransmembrane protein 45BKidney-4.930.001
119ATP6V1C2ATPase, H+ transporting, lysosomal 42kDa, V1 subunit C2Kidney-4.920.000
120BHMTbetaine--homocysteine S-methyltransferaseKidney-4.920.001
121DUSP9dual specificity phosphatase 9Kidney-4.920.000
122TFAP2Atranscription factor AP-2 alpha (activating enhancer binding protein 2 alpha)Kidney-4.910.000
123VAT1Lvesicle amine transport 1-likeKidney-4.910.000
124EMCNendomucinKidney-4.900.000
125TSPAN8tetraspanin 8Kidney-4.900.006
126SIM2single-minded family bHLH transcription factor 2Kidney-4.900.000
127PLGplasminogenKidney-4.890.000
128DMRT2doublesex and mab-3 related transcription factor 2Kidney-4.890.000
129KHKketohexokinase (fructokinase)Kidney-4.890.000
130HRGhistidine-rich glycoproteinKidney-4.880.000
131ACPPacid phosphatase, prostateKidney-4.860.000
132TMEM72transmembrane protein 72Kidney-4.850.000
133DACH1dachshund family transcription factor 1Kidney-4.850.001
134PTGDSprostaglandin D2 synthase 21kDa (brain)Kidney-4.830.001
135AHNAK2AHNAK nucleoprotein 2Kidney+4.830.000
136IRX1iroquois homeobox 1Kidney-4.810.000
137FOLH1folate hydrolase (prostate-specific membrane antigen) 1Kidney-4.810.000
138ATP6V0D2ATPase, H+ transporting, lysosomal 38kDa, V0 subunit d2Kidney-4.800.000
139LOC149703uncharacterized LOC149703Kidney-4.800.001
140TOP2Atopoisomerase (DNA) II alphaKidney+4.780.001
141GATA3GATA binding protein 3Kidney-4.780.000
142FGF1fibroblast growth factor 1 (acidic)Kidney-4.760.000
143ELF5E74-like factor 5 (ets domain transcription factor)Kidney-4.760.000
144KCNE1potassium channel, voltage gated subfamily E regulatory beta subunit 1Kidney-4.750.000
145SEMA3Gsema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3GKidney-4.740.000
146CASRcalcium-sensing receptorKidney-4.740.001
147ANGPTL3angiopoietin-like 3Kidney-4.720.000
148SLC34A1solute carrier family 34 (type II sodium/phosphate cotransporter), member 1Kidney-4.710.000
149PAHphenylalanine hydroxylaseKidney-4.710.000
150ERICH4glutamate-rich 4Kidney-4.700.000
151CLCNKBchloride channel, voltage-sensitive KbKidney-4.700.000
152TFAP2Btranscription factor AP-2 beta (activating enhancer binding protein 2 beta)Kidney-4.690.001
153SLC13A2solute carrier family 13 (sodium-dependent dicarboxylate transporter), member 2Kidney-4.680.001
154CA4carbonic anhydrase IVKidney-4.670.000
155FCN3ficolin (collagen/fibrinogen domain containing) 3Kidney-4.670.000
156TFPI2tissue factor pathway inhibitor 2Kidney+4.590.000
157SLFN13schlafen family member 13Kidney+4.520.000
158CCL18chemokine (C-C motif) ligand 18 (pulmonary and activation-regulated)Kidney+4.490.029
159VCANversicanKidney+4.450.003
160ALOX5arachidonate 5-lipoxygenaseKidney+4.430.000
161LCN2lipocalin 2Kidney+4.330.000
162LRRC20leucine rich repeat containing 20Kidney+4.250.000
163C3complement component 3Kidney+4.240.001
164ABHD11abhydrolase domain containing 11Kidney+4.000.000
165HK2hexokinase 2Kidney+3.980.000
166SEC16BSEC16 homolog B, endoplasmic reticulum export factorKidney+3.980.000
167ABCB4ATP-binding cassette, sub-family B (MDR/TAP), member 4Kidney+3.910.002
168NRTNneurturinKidney+3.840.002
169DNM1dynamin 1Kidney+3.810.000
170LOC100289026uncharacterized LOC100289026Kidney+3.800.002
171HOXA1homeobox A1Kidney+3.800.000
172LYPD1LY6/PLAUR domain containing 1Kidney+3.760.019
173C3orf67chromosome 3 open reading frame 67Kidney+3.760.000
174TREM2triggering receptor expressed on myeloid cells 2Kidney+3.760.000
175HAVCR1hepatitis A virus cellular receptor 1Kidney+3.670.000
176HTRA4HtrA serine peptidase 4Kidney+3.620.002
177CXCL6chemokine (C-X-C motif) ligand 6Kidney+3.610.036
178F12coagulation factor XII (Hageman factor)Kidney+3.570.004
179BCANbrevicanKidney+3.560.001
180CCND2cyclin D2Kidney+3.550.000
181LRRN4leucine rich repeat neuronal 4Kidney+3.520.000
182C15orf48chromosome 15 open reading frame 48Kidney+3.500.015
183BRIP1BRCA1 interacting protein C-terminal helicase 1Kidney+3.500.001
184NAV3neuron navigator 3Kidney+3.480.007
185TPX2TPX2, microtubule-associatedKidney+3.420.013
186NNMTnicotinamide N-methyltransferaseKidney+3.420.004
187SCG5secretogranin VKidney+3.380.020
188HS3ST1heparan sulfate (glucosamine) 3-O-sulfotransferase 1Kidney+3.370.004
189HIST1H2AGhistone cluster 1, H2agKidney+3.350.024
190C1orf186chromosome 1 open reading frame 186Kidney+3.320.001
191MNX1motor neuron and pancreas homeobox 1Kidney+3.240.000
192ONECUT2one cut homeobox 2Kidney+3.230.013
193CD86CD86 moleculeKidney+3.200.001
194TTKTTK protein kinaseKidney+3.190.012
195NEK2NIMA-related kinase 2Kidney+3.160.033
196KIF20Akinesin family member 20AKidney+3.140.027
197TEN1TEN1 CST complex subunitKidney+3.140.013
198TLCD2TLC domain containing 2Kidney+3.130.007
199LOC340340uncharacterized LOC340340Kidney+3.100.023
200UNC5Aunc-5 netrin receptor AKidney+3.070.045
201FANCIFanconi anemia, complementation group IKidney+3.060.011
202CDHR1cadherin-related family member 1Kidney+3.060.026
203MIR155HGMIR155 host geneKidney+3.040.018
204CDH6cadherin 6, type 2, K-cadherin (fetal kidney)Kidney+3.030.000
205ARL11ADP-ribosylation factor-like 11Kidney+3.030.028
206TPK1thiamin pyrophosphokinase 1Kidney+3.020.002
207BCL2A1BCL2-related protein A1Kidney+3.020.022

Search GEO for disease gene expression data for Renal Cell Carcinoma, Papillary.

Pathways for genes affiliated with Renal Cell Carcinoma, Papillary

About this section

Pathways related to Renal Cell Carcinoma, Papillary according to GeneCards Suite gene sharing:

idSuper pathwaysScoreTop Affiliating Genes
19.4ASPSCR1, MET, PAX8, PRCC, TFE3
29.3FH, KIT, MET, MITF, PAX8

GO Terms for genes affiliated with Renal Cell Carcinoma, Papillary

About this section

Biological processes related to Renal Cell Carcinoma, Papillary according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1positive regulation of Notch signaling pathwayGO:004574710.1KIT, RFNG
2positive regulation of transcription from RNA polymerase II promoterGO:00459449.4FLCN, MET, MITF, PAX8, TFE3

Sources for Renal Cell Carcinoma, Papillary

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet